Advances in ovarian cancer treatment using a combination of statins with other drugs

New anti-cancer drugs are constantly being developed, especially targeted drugs. Although these drugs have achieved significant clinical efficacy, they do not play a significant role in ovarian cancer. Moreover, the research cycle and costs of such drugs are often huge. The repositioning of conventi...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 1048484
Main Authors Xia, Lei, Ding, Shichao, Wang, Xuezhen, Zhang, Xiaoyu, Zhu, Lin, Zhang, Hairong, Li, Huirong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 04.01.2023
Subjects
HMGCoA reductase
ovarian cancer
Pharmacology
progress
statins
synergistic effect
HMGCoA reductase
progress
ovarian cancer
statins
synergistic effect
Online AccessGet full text

Cover

More Information
Summary:New anti-cancer drugs are constantly being developed, especially targeted drugs. Although these drugs have achieved significant clinical efficacy, they do not play a significant role in ovarian cancer. Moreover, the research cycle and costs of such drugs are often huge. The repositioning of conventional drugs has gradually become a concern. Statins, as traditional lipid-lowering drugs, play a role mainly by inhibiting HMGCR. In recent years, epidemiological studies and experiments have confirmed its anti-cancer effect, especially the effect of anti-ovarian cancer. The mutation rate of TP53 in ovarian cancer is as high as 95%, while HMGCR is often highly expressed in TP53 mutant tumors. However, the effect of prospective clinical trials is not ideal. This result seems understandable considering that it seems unrealistic for a lipid-lowering drug to completely inhibit tumor growth. Therefore, statins play more synergistic roles in the treatment of ovarian cancer. Because ovarian cancer is a highly heterogeneous tumor, it may be a good choice to deeply understand the mechanism of statins in the treatment of ovarian cancer and achieve precise treatment by combining it with other drugs.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Prem P. Kushwaha, Case Western Reserve University, United States
Balaji Chandrasekaran, Texas A&M University, United States
Annapurna Gupta, Comprehensive Cancer Center, United States
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Edited by: Eswar Shankar, The Ohio State University, United States
These authors have contributed equally to this work and share first authorship
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.1048484